ArticleFrontiers in cardiovascular medicine2026
Efficacy and safety of Shenqi Yangxin formula in patients with stable coronary artery disease based on CCTA: rationale, design, and study protocol for a randomized, double-blind, placebo-controlled study.
Xinyu Zhang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.